Measurement of renal function in patients with chronic kidney disease

British Journal of Clinical Pharmacology

Volumn 76, Issue 4, 2013, Pages 504-515

  Sandilands, Euan A ^a   Dhaun, Neeraj ^a,b   Dear, James W ^a,b   Webb, David J ^b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Chronic kidney disease; Glomerular filtration rate; Renal dysfunction

Indexed keywords

CREATININE; CYSTATIN C; EDETATE CHROMIUM CR 51; FATTY ACID BINDING PROTEIN; INULIN; KIDNEY INJURY MOLECULE 1; N(G),N(G) DIMETHYLARGININE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PENTETATE TECHNETIUM TC 99M; TAMM HORSFALL GLYCOPROTEIN;

4 AMINOHIPPURIC ACID CLEARANCE; ACUTE KIDNEY FAILURE; ARTICLE; BLADDER CATHETERIZATION; BODY MASS; BODY SURFACE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CIRCADIAN RHYTHM; CLINICAL PRACTICE; CONCENTRATION (PARAMETERS); CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HUMAN; INULIN CLEARANCE; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; KIDNEY SIZE; MOLECULAR WEIGHT; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SENSITIVITY AND SPECIFICITY; SODIUM RESTRICTION; THYROID FUNCTION; URINARY EXCRETION; URINE FLOW RATE;

CHRONIC KIDNEY DISEASE; GLOMERULAR FILTRATION RATE; RENAL DYSFUNCTION;

BIOLOGICAL MARKERS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; RENAL INSUFFICIENCY, CHRONIC;

EID: 84884699219     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12198     Document Type: Article

References (131)

1. Levey AS, Tangri N, Stevens LA. Classification of chronic kidney disease: a step forward. Ann Intern Med 2011; 154: 65-67.
2. Levey AS, Andreoli SP, DuBose T, Provenzano R, Collins AJ. CKD: common, harmful, and treatable - World Kidney Day 2007. Am J Kidney Dis 2007; 49: 175-179.
3. Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA, Hostetter TH. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. JASN 2005; 16: 180-188.
4. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
5. de Zeeuw D, Hillege HL, de Jong PE. The kidney, a cardiovascular risk marker, and a new target for therapy. Kidney Int Suppl 2005; 98: S25-29.
6. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.
7. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, Wiebe N, Tonelli M. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423-429.
8. Hemmelgarn BR, Manns BJ, Straus S, Naugler C, Holroyd-Leduc J, Braun TC, Levin A, Klarenbach S, Lee PF, Hafez K, Schwartz D, Jindal K, Ervin K, Bello A, Turin TC, McBrien K, Elliott M, Tonelli M. Knowledge translation for nephrologists: strategies for improving the identification of patients with proteinuria. J Nephrol 2012; 25: 933-943.
9. Matsushita K, Ballew SH, Astor BC, Jong PE, Gansevoort RT, Hemmelgarn BR, Levey AS, Levin A, Wen CP, Woodward M, Coresh J. Cohort profile: the chronic kidney disease prognosis consortium. Int J Epidemiol 2012. [epub ahead of print].
10. Rahn KH, Heidenreich S, Bruckner D. How to assess glomerular function and damage in humans. J Hypertens 1999; 17: 309-317.
11. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483.
12. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. JASN 2009; 20: 2305-2313.
13. Smith HW, Goldring W, Chasis H. The measurement of the tubular excretory mass, effective blood flow and filtration rate in the normal human kidney. J Clin Invest 1938; 17: 263-278.
14. Earle DP, Jr, Berliner RW. A simplified clinical procedure for measurement of glomerular filtration rate and renal plasma flow. Proc Soc Exp Biol Med 1946; 62: 262-264.
15. Berger EY, Farber SJ, Earle DP, Jr. Comparison of the constant infusion and urine collection techniques for the measurement of renal function. J Clin Invest 1948; 27: 710-716.
16. Schnurr E, Lahme W, Kuppers H. Measurement of renal clearance of inulin and PAH in the steady state without urine collection. Clin Nephrol 1980; 13: 26-29.
17. Hellerstein S, Berenbom M, Alon U, Warady BA. The renal clearance and infusion clearance of inulin are similar, but not identical. Kidney Int 1993; 44: 1058-1061.
18. Cotlove E. Mechanism and extent of distribution of inulin and sucrose in chloride space of tissues. Am J Physiol 1954; 176: 396-410.
19. Florijn KW, Barendregt JN, Lentjes EG, van Dam W, Prodjosudjadi W, van Saase JL, van Es LA, Chang PC. Glomerular filtration rate measurement by 'single-shot' injection of inulin. Kidney Int 1994; 46: 252-259.
20. Dhaun N, MacIntyre IM, Kerr D, Melville V, Johnston NR, Haughie S, Goddard J, Webb DJ. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011; 57: 772-779.
21. Sandilands EA, Cameron S, Paterson F, Donaldson S, Briody L, Crowe J, Donnelly J, Thompson A, Johnston NR, Mackenzie I, Uren N, Goddard J, Webb DJ, Megson IL, Bateman N, Eddleston M. Mechanisms for an effect of acetylcysteine on renal function after exposure to radio-graphic contrast material: study protocol. BMC Clin Pharmacol 2012; 12: 3.
22. Odlind B, Hallgren R, Sohtell M, Lindstrom B. Is 125I iothalamate an ideal marker for glomerular filtration? Kidney Int 1985; 27: 9-16.
23. Traynor J, Mactier R, Geddes CC, Fox JG. How to measure renal function in clinical practice. BMJ 2006; 333: 733-737.
24. Perrone RD, Steinman TI, Beck GJ, Skibinski CI, Royal HD, Lawlor M, Hunsicker LG. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis 1990; 16: 224-235.
25. Israelit AH, Long DL, White MG, Hull AR. Measurement of glomerular filtration rate utilizing a single subcutaneous injection of 125I-iothalamate. Kidney Int 1973; 4: 346-349.
26. Rehling M, Moller ML, Thamdrup B, Lund JO, Trap-Jensen J. Simultaneous measurement of renal clearance and plasma clearance of 99mTc-labelled diethylenetriaminepenta-acetate, 51Cr-labelled ethylenediaminetetra-acetate and inulin in man. Clin Sci (Lond) 1984; 66: 613-619.
27. Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. JASN 1995; 6: 257-263.
28. Krutzen E, Back SE, Nilsson-Ehle I, Nilsson-Ehle P. Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. J Lab Clin Med 1984; 104: 955-961.
29. Schwartz GJ, Furth S, Cole SR, Warady B, Munoz A. Glomerular filtration rate via plasma iohexol disappearance: pilot study for chronic kidney disease in children. Kidney Int 2006; 69: 2070-2077.
30. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-226.
31. Mayersohn M, Conrad KA, Achari R. The influence of a cooked meat meal on creatinine plasma concentration and creatinine clearance. Br J Clin Pharmacol 1983; 15: 227-230.
32. Berlyne GM, Varley H, Nilwarangkur S, Hoerni M. Endogenous-creatinine clearance and glomerular-filtration rate. Lancet 1964; 2: 874-876.
33. Dubb JW, Stote RM, Familiar RG, Lee K, Alexander F. Effect of cimetidine on renal function in normal man. Clin Pharmacol Ther 1978; 24: 76-83.
34. Berglund F, Killander J, Pompeius R. Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. J Urol 1975; 114: 802-808.
35. Stevens LA, Levey AS. Measurement of kidney function. Med Clin North Am 2005; 89: 457-473.
36. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28: 830-838.
37. Spanaus KS, Kollerits B, Ritz E, Hersberger M, Kronenberg F, von Eckardstein A. Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin Chem 2010; 56: 740-749.
38. Dalton RN. Serum creatinine and glomerular filtration rate: perception and reality. Clin Chem 2010; 56: 687-689.
39. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47: 312-318.
40. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem 2005; 38: 1-8.
41. Grubb A, Simonsen O, Sturfelt G, Truedsson L, Thysell H. Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand 1985; 218: 499-503.
42. Simonsen O, Grubb A, Thysell H. The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 1985; 45: 97-101.
43. Harmoinen AP, Kouri TT, Wirta OR, Lehtimaki TJ, Rantalaiho V, Turjanmaa VM, Pasternack AI. Evaluation of plasma cystatin C as a marker for glomerular filtration rate in patients with type 2 diabetes. Clin Nephrol 1999; 52: 363-370.
44. Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindstrom V, Grubb A. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 1994; 40: 1921-1926.
45. Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, Vera M, Piera C, Darnell A. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36: 29-34.
46. Stickle D, Cole B, Hock K, Hruska KA, Scott MG. Correlation of plasma concentrations of cystatin C and creatinine to inulin clearance in a pediatric population. Clin Chem 1998; 44: 1334-1338.
47. Ribichini F, Gambaro G, Graziani MS, Pighi M, Pesarini G, Pasoli P, Anselmi M, Ferrero V, Yabarek T, Sorio A, Rizzotti P, Lupo A, Vassanelli C. Comparison of serum creatinine and cystatin C for early diagnosis of contrast-induced nephropathy after coronary angiography and interventions. Clin Chem 2012; 58: 458-464.
48. Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K. Serum cystatin C in the aged: relationships with health status. Am J Kidney Dis 2003; 42: 36-43.
49. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-1421.
50. Kimmel M, Braun N, Alscher MD. Influence of thyroid function on different kidney function tests. Kidney Blood Press Res 2012; 35: 9-17.
51. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
52. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
53. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
54. Poge U, Gerhardt T, Palmedo H, Klehr HU, Sauerbruch T, Woitas RP. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 2005; 5: 1306-1311.
55. Verhave JC, Fesler P, Ribstein J, du Cailar G, Mimran A. Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis 2005; 46: 233-241.
56. Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, Rahman M, Deysher AE, Zhang YL, Schmid CH, Levey AS. Evaluation of the modification of diet in renal disease study equation in a large diverse population. JASN 2007; 18: 2749-2757.
57. Coresh J, Astor BC, McQuillan G, Kusek J, Greene T, Van Lente F, Levey AS. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002; 39: 920-929.
58. Murthy K, Stevens LA, Stark PC, Levey AS. Variation in the serum creatinine assay calibration: a practical application to glomerular filtration rate estimation. Kidney Int 2005; 68: 1884-1887.
59. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. JASN 2006; 17: 2937-2944.
60. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Hirakata H, Watanabe T, Moriyama T, Ando Y, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11: 41-50.
61. Mahajan S, Mukhiya GK, Singh R, Tiwari SC, Kalra V, Bhowmik DM, Gupta S, Agarwal SK, Dash SC. Assessing glomerular filtration rate in healthy Indian adults: a comparison of various prediction equations. J Nephrol 2005; 18: 257-261.
62. Praditpornsilpa K, Townamchai N, Chaiwatanarat T, Tiranathanagul K, Katawatin P, Susantitaphong P, Trakarnvanich T, Kanjanabuch T, Avihingsanon Y, Tungsanga K, Eiam-Ong S. The need for robust validation for MDRD-based glomerular filtration rate estimation in various CKD populations. Nephrol Dial Transplant 2011; 26: 2780-2785.
63. Feng JF, Qiu L, Zhang L, Li XM, Yang YW, Zeng P, Guo XZ, Qin Y, Liu HC, Han XM, Li YP, Xu W, Sun SY, Wang LQ, Quan H, Xia LJ, Hu HZ, Zhong FC, Duan R. Multicenter study of creatinine- and/or cystatin C-based equations for estimation of glomerular filtration rates in chinese patients with chronic kidney disease. PLoS ONE 2013; 8: e57240.
64. Robles NR, Mena C, Cidoncha J. Estimated glomerular filtration rate from serum cystatin C: significant differences among several equations results. Ren Fail 2012; 34: 871-875.
65. Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum cystatin C-based formulas for prediction of glomerular filtration rate in patients with chronic kidney disease. Nephron Clin Pract 2010; 114: c118-126.
66. Masson I, Maillard N, Tack I, Thibaudin L, Dubourg L, Delanaye P, Cavalier E, Bonneau C, Kamar N, Morelon E, Moranne O, Alamartine E, Mariat C. GFR estimation using standardized cystatin C in kidney transplant recipients. Am J Kidney Dis 2013; 61: 279-284.
67. Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012; 156: 785-795, W-270, W-71, W-72, W-73, W-74, W-75, W-76, W-77, W-78.
68. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
69. Viswanathan G, Upadhyay A. Assessment of proteinuria. Adv Chronic Kidney Dis 2011; 18: 243-248.
70. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? JASN 2006; 17: 2974-2984.
71. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-296.
72. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes. J Nephrol 2008; 21: 566-569.
73. Price CP, Newall RG, Boyd JC. Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. Clin Chem 2005; 51: 1577-1586.
74. Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983; 309: 1543-1546.
75. Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M, Azevedo MJ. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997; 20: 516-519.
76. Rodby RA, Rohde RD, Sharon Z, Pohl MA, Bain RP, Lewis EJ. The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Am J Kidney Dis 1995; 26: 904-909.
77. Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ 1998; 316: 504-509.
78. Guy M, Borzomato JK, Newall RG, Kalra PA, Price CP. Protein and albumin-to-creatinine ratios in random urines accurately predict 24h protein and albumin loss in patients with kidney disease. Ann Clin Biochem 2009; 46: 468-476.
79. Methven S, MacGregor MS, Traynor JP, O'Reilly DS, Deighan CJ. Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio. Nephrol Dial Transplant 2010; 25: 2991-2996.
80. Lambers Heerspink HJ, Gansevoort RT, Brenner BM, Cooper ME, Parving HH, Shahinfar S, de Zeeuw D. Comparison of different measures of urinary protein excretion for prediction of renal events. JASN 2010; 21: 1355-1360.
81. Lamb EJ, MacKenzie F, Stevens PE. How should proteinuria be detected and measured? Ann Clin Biochem 2009; 46: 205-217.
82. National Institute for Health and Clinical Excellence (NICE). Chronic kidney disease. [online]. Available at http://www.nice.org.uk/cg73 (last accessed 25 July 2013).
83. Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of chronic kidney disease. [online]. Available at http://www.sign.ac.uk/guidelines/fulltext/103/ (last accessed 25 July 2013).
84. Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B, Hostetter T. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009; 54: 205-226.
85. Towler JD, Dhaun N, Macdougall M, Melville V, Goddard J, Webb DJ. What is the best method of proteinuria measurement in clinical trials of endothelin receptor antagonists? Life Sci 2012; 91: 733-738.
86. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165: 947-953.
87. Toto RD. Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and para-aminohippuric acid clearance. Curr Opin Nephrol Hypertens 1995; 4: 505-509; discussion 03-4.
88. Brenna S, Grigoras O, Drukker A, Guignard JP. Pitfalls in measuring inulin and para-amino-hippuric acid clearances. Pediatr Nephrol 1998; 12: 489-491.
89. Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 2007; 50: 169-180.
90. Devarajan P. The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis 2010; 17: 469-479.
91. Woods LL. Intrarenal mechanisms of renal reserve. Semin Nephrol 1995; 15: 386-395.
92. Chaudhary K, Phadke G, Nistala R, Weidmeyer CE, McFarlane SI, Whaley-Connell A. The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep 2010; 10: 37-42.
93. Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17: 127-132.
94. Leung KC, Tonelli M, James MT. Chronic kidney disease following acute kidney injury-risk and outcomes. Nat Rev Nephrol 2012; 9: 77-85.
95. Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int 2012; 82: 516-524.
96. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. JASN 2003; 14: 2534-2543.
97. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996; 38: 414-420.
98. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int 2007; 71: 967-970.
99. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Li JY, Weiss S, Mishra J, Cheema FH, Markowitz G, Suganami T, Sawai K, Mukoyama M, Kunis C, D'Agati V, Devarajan P, Barasch J. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005; 115: 610-621.
100. Bolignano D, Coppolino G, Lacquaniti A, Nicocia G, Buemi M. Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin in macroproteinuric patients with worsening renal function. Kidney Blood Press Res 2008; 31: 274-279.
101. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. CJASN 2009; 4: 337-344.
102. Mitsnefes MM, Kathman TS, Mishra J, Kartal J, Khoury PR, Nickolas TL, Barasch J, Devarajan P. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol 2007; 22: 101-108.
103. Kasahara M, Mori K, Satoh N, Kuwabara T, Yokoi H, Shimatsu A, Sugawara A, Mukoyama M, Nakao K. Reduction in urinary excretion of neutrophil gelatinase-associated lipocalin by angiotensin receptor blockers in hypertensive patients. Nephrol Dial Transplant 2009; 24: 2608-2609; author reply 09-10.
104. Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, Yoshioka T, Ogawa Y, Imamaki H, Kusakabe T, Ebihara K, Omata M, Satoh N, Sugawara A, Barasch J, Nakao K. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int 2009; 75: 285-294.
105. Devarajan P. Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle. Cancer Ther 2007; 5: 463-470.
106. Devarajan P. The promise of biomarkers for personalized renal cancer care. Kidney Int 2010; 77: 755-757.
107. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008; 48: 463-493.
108. Ichimura T, Brooks CR, Bonventre JV. Kim-1/Tim-1 and immune cells: shifting sands. Kidney Int 2012; 81: 809-811.
109. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002; 62: 237-244.
110. Zhang Z, Humphreys BD, Bonventre JV. Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region. JASN 2007; 18: 2704-2714.
111. Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H, MacKinnon RW, Li L, Balakrishnan VS, Pereira BJ, Bonventre JV, Urinary JBL. N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. JASN 2007; 18: 904-912.
112. Vaidya VS, Ford GM, Waikar SS, Wang Y, Clement MB, Ramirez V, Glaab WE, Troth SP, Sistare FD, Prozialeck WC, Edwards JR, Bobadilla NA, Mefferd SC, Bonventre JV. A rapid urine test for early detection of kidney injury. Kidney Int 2009; 76: 108-114.
113. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 2007; 212: 209-217.
114. van Timmeren MM, Vaidya VS, van Ree RM, Oterdoom LH, de Vries AP, Gans RO, van Goor H, Stegeman CA, Bonventre JV, Bakker SJ. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation 2007; 84: 1625-1630.
115. Waanders F, Vaidya VS, van Goor H, Leuvenink H, Damman K, Hamming I, Bonventre JV, Vogt L, Navis G. Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis 2009; 53: 16-25.
116. Conway BR, Manoharan D, Manoharan D, Jenks S, Dear JW, McLachlan S, Strachan MW, Price JF. Measuring urinary tubular biomarkers in type 2 diabetes does not add prognostic value beyond established risk factors. Kidney Int 2012; 82: 812-818.
117. Portilla D, Dent C, Sugaya T, Nagothu KK, Kundi I, Moore P, Noiri E, Devarajan P. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 2008; 73: 465-472.
118. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Omata M, Kimura K. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 2006; 284: 175-182.
119. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17: 609-615.
120. Sharma M, Zhou Z, Miura H, Papapetropoulos A, McCarthy ET, Sharma R, Savin VJ, Lianos EA. ADMA injures the glomerular filtration barrier: role of nitric oxide and superoxide. American journal of physiology. Ren Physiol 2009; 296: F1386-1395.
121. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. JASN 2004; 15: 1677-1689.
122. Final Conclusions on the Pilot Joint EMEA/FDA VXDS Experience on Qualification of Nephrotoxicity Biomarkers. London: European Medicines Agency, 2009. [online] Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004205.pdf (last accessed 29 July 2013).
123. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. JASN 2006; 17: 17-25.
124. Inoue T, Kozawa E, Okada H, Inukai K, Watanabe S, Kikuta T, Watanabe Y, Takenaka T, Katayama S, Tanaka J, Suzuki H. Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging. JASN 2011; 22: 1429-1434.
125. Heyman SN, Khamaisi M, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia response and the progression of chronic kidney disease. Am J Nephrol 2008; 28: 998-1006.
126. Penfield JG, Reilly RF. Gadolinium and nephrogenic systemic fibrosis: have we overreacted? Semin Dial 2011; 24: 480-486.
127. Thoeny HC, De Keyzer F, Oyen RH, Peeters RR. Diffusion-weighted MR imaging of kidneys in healthy volunteers and patients with parenchymal diseases: initial experience. Radiology 2005; 235: 911-917.
128. Togao O, Doi S, Kuro-o M, Masaki T, Yorioka N, Takahashi M. Assessment of renal fibrosis with diffusion-weighted MR imaging: study with murine model of unilateral ureteral obstruction. Radiology 2010; 255: 772-780.
129. Xu X, Fang W, Ling H, Chai W, Chen K. Diffusion-weighted MR imaging of kidneys in patients with chronic kidney disease: initial study. Eur Radiol 2010; 20: 978-983.
130. Schachinger H, Klarhofer M, Linder L, Drewe J, Scheffler K. Angiotensin II decreases the renal MRI blood oxygenation level-dependent signal. Hypertension 2006; 47: 1062-1066.
131. Michaely HJ, Metzger L, Haneder S, Hansmann J, Schoenberg SO, Attenberger UI. Renal BOLD-MRI does not reflect renal function in chronic kidney disease. Kidney Int 2012; 81: 684-689.